GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ainos Inc.
Ainos is a diversified company developing both diagnostic tests and pharmaceuticals. Its stock price reflects progress across all its programs. Its price is volatile and driven by news from the laboratory and regulators.
Share prices of companies in the market segment - Medanalysis
Ainos, Inc. is a diversified company developing both volatile organic compound-based diagnostic tests and pharmaceuticals. We've classified it as a "Medanalysis" company. The chart below shows how the market values companies with a mixed business model in healthcare.
Broad Market Index - GURU.Markets
Ainos is a company that develops diagnostic tests and therapeutic drugs based on volatile organic compounds. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the industry's prospects.
Change in the price of a company, segment, and market as a whole per day
AIMD - Daily change in the company's share price Ainos Inc.
Ainos, Inc.'s daily stock price fluctuations reflect the high volatility of the medical diagnostics sector. The metric demonstrates sensitivity to news regarding the development and commercialization of its diagnostic tests.
Daily change in the price of a set of shares in a market segment - Medanalysis
Ainos, Inc. is a medical diagnostics company. This chart highlights the sector's high volatility. Comparison with AIMD's performance, which depends on the approval of new tests, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Ainos is a company specializing in rapid diagnostics for infectious diseases. Demand for its products can spike during epidemics, creating a unique, event-driven dynamic in its stock that impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ainos Inc.
Ainos, Inc.'s year-to-date performance tells the story of its diversified development portfolio. Its trailing 12-month market cap reflects progress across its various programs, from volatile organic compound-based diagnostic tests to pharmaceuticals, making its valuation dependent on news from multiple areas.
Annual dynamics of market capitalization of the market segment - Medanalysis
Ainos, Inc. is a diversified company developing both diagnostic tests and pharmaceuticals. Its stock price is highly volatile, reflecting both the potential of its R&D and the risks associated with its complex and diverse strategy in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ainos, a diversified diagnostics and pharmaceutical company, is a hybrid story. Its dynamics are a balance between stable revenue from testing and speculative hopes for new drugs. A comparison with the market reveals which of these factors currently has the greater impact on investor valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ainos Inc.
Ainos is a biotech company developing diagnostic tests and drugs. Its monthly performance reflects the cumulative news across its various programs. Progress in any of them, whether COVID tests or potency drugs, could impact its valuation.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Ainos is a company developing rapid diagnostic tests and therapeutic drugs based on volatile organic compounds (VOCs) found in human exhaled air. The graph below illustrates the overall dynamics in the medical analysis sector, where the search for non-invasive and rapid diagnostic methods is the Holy Grail.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of small diagnostic companies can be highly volatile and speculative. The chart below shows the overall risk appetite. Is Ainos, Inc. moving at an elevated rate, or is its success in test development creating its own trend?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ainos Inc.
Ainos, a developer of a diversified portfolio of diagnostic tests and pharmaceuticals, exhibits high volatility. Its weekly share price performance reflects a flurry of news about its various programs, from COVID-19 testing and other virus testing to the development of dementia treatments.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Ainos, like other companies in the medical diagnostics sector, is dependent on overall healthcare trends. Demand for tests and genetic analysis are common factors for all. The chart shows how AIMD's diversified business is performing compared to the industry average.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ainos, Inc., as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how AIMD shares can rise or fall on its own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
AIMD - Market capitalization of the company Ainos Inc.
The Ainos chart is likely a story about diagnostic technologies. The company's market capitalization dynamics reflect investor expectations for its tests and analytical instruments. Its movements reflect the market's speculative assessment of its developments and their potential to improve medical diagnostics.
AIMD - Share of the company's market capitalization Ainos Inc. within the market segment - Medanalysis
Ainos is a medical diagnostics company. Its market share will reflect the accuracy and demand for its tests. The chart will assess its competitive position in an industry where the speed and reliability of diagnostics are key to treating diseases.
Market capitalization of the market segment - Medanalysis
Ainos is a company focused on diagnostics based on volatile organic compounds (e.g., in exhaled breath). The chart below shows the market capitalization of the medical analysis sector. This represents the valuation of a breakthrough technology that could make disease diagnosis fast and non-invasive.
Market capitalization of all companies included in a broad market index - GURU.Markets
Ainos is a company developing and commercializing diagnostic tests and pharmaceuticals. Its market capitalization reflects the potential of its molecular diagnostics technologies. The chart below shows the economic weight of the medical testing sector.
Book value capitalization of the company, segment and market as a whole
AIMD - Book value capitalization of the company Ainos Inc.
Ainos's book value is derived from its portfolio of diagnostic technologies. Its foundation consists of patents for a platform for creating rapid tests for various diseases, as well as R&D laboratories for developing new products. The chart below shows how the company is building its scientific and financial foundation in the field of rapid diagnostics.
AIMD - Share of the company's book capitalization Ainos Inc. within the market segment - Medanalysis
Ainos, Inc. relies on its R&D labs and production lines to develop diagnostic tests. The S_BCap_Seg graph shows its share of the physical infrastructure in the medical testing sector.
Market segment balance sheet capitalization - Medanalysis
Ainos is a diversified company operating in medical diagnostics and consumer electronics. This combination requires both laboratories and production lines. The chart shows how these disparate but tangible assets shape its business.
Book value of all companies included in the broad market index - GURU.Markets
Ainos' assets are focused on the development of rapid diagnostic tests. The company's book value reflects its R&D laboratories and the rights to the technology that enables the creation of portable tests based on volatile organic compounds. This provides the foundation for developing non-invasive and rapid diagnostics for various diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ainos Inc.
Ainos is a company developing diagnostic tests and pharmaceuticals. Its book value is small. Its market capitalization is a measure of its diversified portfolio, including tests for volatile organic compounds and potential drugs, and investors' confidence in the success of these developments.
Market to book capitalization ratio in a market segment - Medanalysis
Ainos is a diversified company developing diagnostic tests and pharmaceuticals. The chart shows how the market values the sum of its various projects compared to their combined book value.
Market to book capitalization ratio for the market as a whole
Ainos is a diversified company developing diagnostic tests and pharmaceuticals. Its valuation is the sum of the potential of its various businesses. The chart shows how the market values this complex entity, which seeks to combine diagnostics and therapeutics.
Debts of the company, segment and market as a whole
AIMD - Company debts Ainos Inc.
Ainos, a company developing diagnostic tests and pharmaceuticals, uses debt to finance its diversified programs. This chart shows capital raising for both the commercialization of its rapid COVID-19/flu tests and preclinical oncology research.
Market segment debts - Medanalysis
Ainos is a company developing diagnostic tests and pharmaceuticals. This hybrid approach requires investment in both R&D and regulatory approvals for its products. This chart shows how the company funds its diverse research programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ainos Inc.
Ainos, Inc. develops diagnostic tests and therapeutic drugs. This chart shows how the diversified biotech company finances its projects. Debt reflects the level of risk management considers acceptable when pursuing multiple developments simultaneously, each requiring significant investment.
Market segment debt to market segment book capitalization - Medanalysis
Ainos, Inc. develops diagnostic tests and pharmaceuticals. This chart for the medical testing and pharmaceuticals sector shows how companies finance their R&D and manufacturing capabilities. It allows one to assess how aggressively the company invests in new product development in a highly competitive environment.
Debt to book value of all companies in the market
Ainos is a diversified company developing diagnostic tests and pharmaceuticals. The debt-to-book value chart helps assess the overall health of the healthcare sector. The investment climate and government funding in this sector directly impact Ainos's ability to commercialize its developments.
P/E of the company, segment and market as a whole
P/E - Ainos Inc.
Ainos is a diversified company developing diagnostic tests (including COVID-19 tests) and pharmaceuticals. This chart reflects investor valuations of its diverse assets. The valuation dynamics depend on both demand for its diagnostics and progress in drug development, creating a complex valuation picture.
P/E of the market segment - Medanalysis
Ainos, Inc. is a diversified company in the healthcare sector. This chart shows the average P/E for this industry. Comparing the company's P/E to this metric helps understand how the market views its hybrid model (diagnostics and pharmaceuticals) and its prospects compared to more focused healthcare companies.
P/E of the market as a whole
Ainos is a diversified company developing diagnostic tests (including COVID tests) and pharmaceuticals. This chart shows sentiment in the healthcare sector. The company's valuation depends on its ability to succeed in both diagnostics and drug development, a complex undertaking requiring diverse competencies and significant investment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ainos Inc.
Ainos is a diversified company developing both diagnostic tests (including COVID-19 tests) and pharmaceuticals. The chart reflects expected future revenue from these different areas. Analysts assess the potential of each segment and their contribution to overall profitability.
%20P%2FE%20Ainos%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ainos-Inc.&v=1772666946517 "Chart of the company's future (projected) P/E Ainos Inc.")
Future (projected) P/E of the market segment - Medanalysis
Ainos is a company developing diagnostic tests and pharmaceuticals. This chart shows how its future revenue expectations compare to the industry average, reflecting its diversified approach, combining diagnostics and therapeutics.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772666946532 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Ainos is a diversified company developing diagnostic tests and pharmaceuticals. Its value is the sum of expectations for several research projects in different fields. It is not linked to general market forecasts, but is determined by research data and product commercialization.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772666946536 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ainos Inc.
Ainos, Inc. is a diversified company developing diagnostic tests (including those for volatile organic compounds) and pharmaceuticals. Its financial metrics are a combination of R&D expenditures across various areas and potential revenue from commercialization. This chart shows how the company manages its portfolio of diverse projects.
Profit of companies in the market segment - Medanalysis
Ainos, Inc. is a diversified company developing medical diagnostic tests and therapeutics. This chart reflects the profitability of the medical analytics sector. Its business combines the development of rapid infectious disease tests with pharmaceutical research. The combined results demonstrate the potential for synergies between diagnostics and treatment.
Overall market profit
Ainos, Inc. is a diversified company operating in the field of medical diagnostics, specifically developing tests for volatile organic compounds (VOCs) to detect diseases. Its success depends on the validation of its technology and its commercialization. This chart illustrates the common economic cycles against which Ainos is attempting to implement an innovative approach to diagnostics.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ainos Inc.
Ainos, Inc. develops diagnostic tests and therapeutics. Its future earnings forecasts presented here reflect the combined expectations for these two businesses. They show how analysts assess the potential of both its diagnostic products and its early-stage pharmaceutical developments.
%20profit%20of%20the%20company%20Ainos%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ainos-Inc.&v=1772666946634 "Graph of future (projected) profit of the company Ainos Inc.")
Future (predicted) profit of companies in the market segment - Medanalysis
Ainos, Inc. develops and markets diagnostic tests and therapeutics, including for COVID-19 and other diseases. This chart shows profitability forecasts for the healthcare analytics sector. It reflects expected demand for rapid and accurate diagnostic solutions.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772666946648 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Ainos, Inc. develops diagnostic tests. Demand for medical diagnostics is stable, but the implementation of new technologies requires investment from the healthcare system. The total revenue forecast, shown in the graph, reflects the overall economic capacity of the government and clinics to fund innovation, which impacts Ainos's growth potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772666946683 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ainos Inc.
Ainos, Inc. develops diagnostic tests and pharmaceuticals. Its revenue is a combination of test sales and potential future royalties. Its P/S ratio helps evaluate its diversified business model in the healthcare sector.
P/S market segment - Medanalysis
Ainos, Inc. is a diversified healthcare company developing diagnostic tests (including COVID-19 tests) and pharmaceuticals. Their business spans several healthcare areas. This chart shows how the market views their multi-pronged strategy and ability to generate revenue from various medical products.
P/S of the market as a whole
Ainos is a company developing diagnostic tests and pharmaceuticals. Revenue is at an early stage and depends on the commercialization of its products. This chart shows the average revenue estimate, which helps understand how the market values the company's revenue for a company operating in two healthcare segments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ainos Inc.
Ainos, Inc. develops rapid diagnostic tests and pharmaceuticals. This chart reflects investor expectations for future revenue from both diagnostic test sales and the potential commercialization of its drug developments.
%20P%2FS%20Ainos%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ainos-Inc.&v=1772666946825 "The graph of the company's future (projected) P/S Ainos Inc.")
Future (projected) P/S of the market segment - Medanalysis
Ainos, Inc. is a diversified medical technology company developing rapid volatile organic compound (VOC)-based tests and pharmaceuticals. This chart shows how the market estimates future revenue from its various businesses. It compares it to other companies in the medical testing sector, reflecting its innovative developments.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772666946855 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Ainos is a company developing diagnostic tests and pharmaceuticals. Its diversified approach targets various segments of the healthcare market. This chart shows revenue expectations for the entire market, and AIMD shows how companies are trying to mitigate risks by pursuing both diagnostics and therapeutics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772666946871 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ainos Inc.
Ainos, Inc. is a diversified company developing rapid diagnostic tests and volatile organic compounds (VOCs) for disease screening, as well as pharmaceuticals. Its revenue in this chart is generated from sales of diagnostic tests and, potentially, from licensing its technologies.
Sales of companies in the market segment - Medanalysis
Ainos is a company that develops diagnostic tests and pharmaceuticals. This chart could segment its revenue, separating revenue from diagnostic product sales and royalties from its pharmaceutical developments. This would demonstrate the balance of its business model.
Overall market sales
Ainos, Inc. develops diagnostic tests and pharmaceuticals. Demand for medical diagnostics and treatments is driven by health conditions, not economics. This timeline is irrelevant to Ainos, whose success depends on the accuracy of its tests, the effectiveness of its drugs, and regulatory approval.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ainos Inc.
Ainos is a company developing diagnostic tests (including COVID-19 tests) and pharmaceuticals. Its revenue forecast reflects expected demand for its diagnostics and progress in drug development. This chart shows how analysts assess its diversified healthcare portfolio.
%20sales%20of%20the%20company%20Ainos%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ainos-Inc.&v=1772666946894 "Schedule of future (projected) sales of the company Ainos Inc.")
Future (projected) sales of companies in the market segment - Medanalysis
Ainos, Inc. develops diagnostic tests and pharmaceuticals. This chart shows projected revenue for the entire medical analytics sector. It reflects the demand for rapid and accurate diagnostic tests for various diseases, which is key to assessing the market potential of Ainos' product line.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772666946905 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Ainos is a company developing diagnostic tests and pharmaceuticals. Its success is diversified and depends on both test sales and progress in R&D. This dynamic of overall economic expectations impacts healthcare system budgets (for tests) and the investment climate (for R&D), creating a complex dynamic for Ainos.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772666946907 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ainos Inc.
Ainos, Inc. is a diversified company developing diagnostic tests and pharmaceuticals. This chart shows the combined performance of its various businesses. Profitability depends on the successful commercialization of both its VOC tests and its drug candidates.
Market segment marginality - Medanalysis
Ainos, Inc. is a diversified biotechnology company developing diagnostic tests (including COVID-19 tests) and therapeutics. This chart shows the average profitability in the medical diagnostics sector. It helps assess how successfully Ainos commercializes its products and manages its development pipeline to achieve profitability.
Market marginality as a whole
Ainos, Inc. develops diagnostic tests and pharmaceuticals. This total profitability chart does not reflect the company's valuation, which depends on the success of its R&D programs and regulatory approvals.
Employees in the company, segment and market as a whole
Number of employees in the company Ainos Inc.
Ainos is a company developing diagnostic tests and pharmaceuticals. Its small team of scientists is working on several projects. This graph illustrates a diversified R&D model, where a small team is developing both diagnostics and therapeutics.
Share of the company's employees Ainos Inc. within the market segment - Medanalysis
Ainos, Inc. is a diversified medical technology company focused on diagnostics and pharmaceuticals. This chart illustrates its multidisciplinary approach. It reflects the proportion of scientists working on volatile organic compounds for diagnostics and researchers developing treatments that Ainos employs.
Number of employees in the market segment - Medanalysis
Ainos, Inc. develops rapid diagnostic tests and treatments. This chart shows employment in the medical analytics sector. The growth in the number of specialists in this field reflects the demand for rapid and accurate point-of-care diagnostics, enabling prompt treatment and infection control.
Number of employees in the market as a whole
Ainos, Inc. is a diversified company operating in the medical diagnostics and consumer electronics industries. Developing rapid and accurate tests for disease detection remains a priority. This chart shows overall employment, with companies operating at the intersection of healthcare and technology driving innovation.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ainos Inc. (AIMD)
Ainos, Inc. operates in the medical diagnostics industry. Its value lies in the accuracy and speed of its tests. This chart shows how the market values the company's technology. Its high market capitalization per employee suggests that its intellectual property has the potential to become a new standard in diagnostics.
%20of%20the%20company%20Ainos%20Inc.%20(AIMD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ainos-Inc.-AIMD&v=1772666946952 "Chart of market capitalization per employee (in thousands of dollars) of the company Ainos Inc. (AIMD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Ainos, Inc. develops diagnostic tests and pharmaceuticals. For such a diversified company, the market value per employee reflects the overall potential of its developments. This metric helps assess which segment—diagnostics or therapeutics—the market values more highly.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772666946954 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Ainos, Inc. develops diagnostic tests and pharmaceuticals. The presence of two lines of business—diagnostics and therapeutics—diversifies its operations. This chart shows how the market evaluates the company's overall potential and its team's ability to develop both.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772666946956 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ainos Inc. (AIMD)
Ainos is a hybrid company. It commercializes rapid diagnostic tests (based on volatile compounds) and also conducts pharmaceutical R&D (antiviral). This chart shows how profitable test sales are and how these revenues (or losses) cover the R&D staff working on drugs.
%20Chart%20Ainos%20Inc.%20(AIMD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ainos-Inc.-AIMD&v=1772666946965 "Company Profit Per Employee (in thousands of dollars) Chart Ainos Inc. (AIMD)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Ainos, Inc. is a diversified company developing volatile organic compound (VOC)-based diagnostic tests and therapeutics. This graph highlights the potential of their technologies. It illustrates the value the company could create by working at the intersection of diagnostics and pharmaceuticals if its innovative approaches prove successful and commercially viable.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772666946975 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Ainos, Inc. (AIMD) is a company developing diagnostic tests (based on volatile organic compounds) and pharmaceuticals. It is a hybrid of diagnostics and biotech. This chart reflects the R&D costs per employee required to validate their diagnostic platform and advance drugs through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772666946995 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ainos Inc. (AIMD)
Ainos, Inc. is a diagnostic testing company. This graph shows the commercialization stage of its products. Increased revenue per employee will indicate successful market launch of the tests, receipt of necessary approvals, and increased sales volumes to laboratories and clinics.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ainos-Inc.-AIMD&v=1772666946998 "Sales chart per company employee Ainos Inc. (AIMD)")
Sales per employee in the market segment - Medanalysis
Ainos (AIMD) is a company developing rapid diagnostic tests based on volatile organic compounds (e.g., exhaled breath) and pharmaceuticals. This chart shows the average revenue per employee in the segment. Comparing AIMD to this benchmark demonstrates how effectively they are commercializing their diagnostic and pharmaceutical developments.
Sales per employee for the market as a whole
Ainos (AIMD) is a company specializing in diagnostics (including volatile organic compounds) and pharmaceuticals. It is an R&D company seeking to commercialize its technologies. While this figure is currently low, its growth will indicate success in bringing its diagnostic devices or drugs to market.
Short shares by company, segment and market as a whole
Shares shorted by company Ainos Inc. (AIMD)
Ainos (AIMD) is a company developing diagnostic tests (including COVID tests) and pharmaceuticals. It's a diversified but very small microcap. This chart shows the bets that none of their businesses will take off. The bears believe their tests are uncompetitive and their drugs are too early.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ainos-Inc.-AIMD&v=1772666947029 "Short Shares Chart for the Company Ainos Inc. (AIMD)")
Shares shorted by market segment - Medanalysis
Ainos (AIMD) is a biotech focused on rapid diagnostics (viral tests) and cancer treatments. This chart shows the pessimism in the sector. The growing short position in the industry is a bet that AIMD won't be able to compete. The rapid diagnostics market has been decimated by giants, and oncology is a biotech graveyard. Investors don't believe in any of the company's businesses.
Shares shorted by the overall market
Ainos is a diagnostics company developing tests (including for COVID). This chart illustrates the overall market pessimism. The market is tired of COVID-19 stories. When investors are afraid, they look at the declining demand for tests and don't believe in the company's ability to quickly bring other products to market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ainos Inc. (AIMD)
This oscillator for Ainos is a barometer of speculation in the rapid diagnostics sector. The company is developing tests (including for COVID and STIs) and even therapeutic drugs. "Overbought" levels (above 70) arise from news of regulatory approval of a new test or from general hype surrounding pandemics. High competition in diagnostics and development delays lead to "oversold" levels.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ainos-Inc.-AIMD&v=1772666947076 "RSI 14 indicator chart for the company's stock Ainos Inc. (AIMD)")
RSI 14 Market Segment - Medanalysis
Ainos is "diagnostics" 2.0. Their AI-powered platform analyzes volatile organic compounds (VOCs - "smell") for early disease detection. The "Medanalysis" (diagnostics) sector thrives on R&D. RSI_14_Seg shows the "temperature" of the entire industry. It helps us understand: is AIMD's growth a niche or just general hype?
RSI 14 for the overall market
Ainos (AIMD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AIMD (Ainos Inc.)
Ainos (AIMD) is a diversified company developing both rapid diagnostic tests (for COVID and flu) and pharmaceuticals. This chart shows the average 12-month forecast. It reflects analysts' assessment of its technology platform and the commercial potential of its developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AIMD-Ainos-Inc.&v=1772666947110 "A chart showing analyst consensus forecasts for the expected stock price. AIMD (Ainos Inc.)")
The difference between the consensus estimate and the actual stock price AIMD (Ainos Inc.)
Ainos is a biotech company developing both diagnostic tests (for COVID and flu) and therapeutic drugs. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their "summary" valuation of this diversified R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AIMD-Ainos-Inc.&v=1772666947120 "A chart showing the difference between the consensus forecast and the actual stock price. AIMD (Ainos Inc.)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Ainos is a diversified biotech company focused on developing rapid diagnostic tests (including an "electronic nose" for volatile compounds) and drug R&D. This chart reflects analysts' overall expectations for the entire medical testing sector. It shows whether experts believe in the future of "instant" diagnostics.
Analysts' consensus forecast for the overall market share price
Ainos is a diversified biotech company developing both rapid diagnostic tests (point-of-care) and pharmaceuticals. This chart shows the overall market "risk appetite." For Ainos, a high-risk clinical-stage company, overall market optimism (as shown by the rising chart) is critical for attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ainos Inc.
Ainos is an R&D company focused on rapid diagnostics. They are developing an AI- and odor-based platform for the instant detection of diseases (COVID, influenza) in exhaled breath, as well as veterinary drugs. This chart is a clear indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative valuation of their futuristic diagnostic platform and their chances of FDA approval.
AKIMA Market Segment Index - Medanalysis
Ainos (AIMD) is a diversified company developing both diagnostic tests (rapid COVID tests, VOCs) and pharmaceuticals, including treatments for sexually transmitted diseases. The chart shows the average index for the segment, helping investors assess how this hybrid diagnostics and pharmaceutical approach compares to the global average.
The AKIM Index for the overall market
Ainos is a diversified medtech and pharmaceutical company developing diagnostics (POCT), drugs (interferon), and consumer products. This chart, reflecting the market average, is a backdrop. It helps assess how AIMD, which combines various healthcare areas, compares to overall macroeconomic trends.
